Use Cases
Sleep
Sleep Onset and Sleep Depth
Delta sleep-inducing peptide has the most promising name and some of the thinnest evidence on this site. That contrast is instructive.
EExperimental / Limited EvidenceReviewed September 1, 2026
Compounds used for this goal
The reason
Why people use it
- Difficulty reaching deep sleep, rather than difficulty falling asleep, is the complaint most often cited.
- DSIP was isolated in the 1970s from rabbit brain during sleep research, and the name alone has carried its reputation for fifty years.
- Epitalon is discussed for circadian and melatonin-rhythm normalisation as part of longevity-oriented use.
The evidence
What the research shows
- DSIP's published human work is old, small and inconsistent; later studies failed to reproduce a reliable sleep-inducing effect, and its name overstates what was demonstrated.
- Epitalon research is dominated by a single Russian research group, which is a significant independence and replication problem.
- Growth-hormone secretagogues have better-documented slow-wave sleep effects than either, which is why they appear in this list at all.
- Sleep is measurable — polysomnography exists — so the absence of modern controlled sleep-architecture data for DSIP is a meaningful gap, not merely a lack of interest.
Reported use
How it is reported to be used
- Evening subcutaneous injection shortly before bed is the standard reported approach.
- Reported effects are inconsistent between individuals, which is what you would expect where controlled evidence is absent.
- Morning grogginess and vivid dreaming are the most reported subjective effects.
Our reading
Evidence verdict
EExperimental / Limited EvidenceVery little published research of any kind. Discussion is largely theoretical or anecdotal.
Experimental. Old, unreplicated human work for DSIP, single-group research for epitalon, and no modern sleep-architecture data for either.
Before you read further
Cautions and open questions
- Insomnia has an effective first-line treatment — cognitive behavioural therapy for insomnia — with far stronger evidence than anything here.
- Sleep apnoea is common, serious and frequently undiagnosed; unrefreshing sleep should be evaluated.
- No long-term safety data exist for either compound.
Sources
Referenced research
- Narrative review
Delta sleep-inducing peptide: published human studies
- Systematic review
Cognitive behavioural therapy for insomnia: systematic review
Educational content only. This page is not medical advice, a protocol or an individualised dosing recommendation. Reported use patterns summarise published literature and community reporting; they are not verified clinical cases and are not endorsements. Speak to a qualified healthcare professional about your own health.
All use cases